Combined treatment of leukemia cells with vitamin K2 and 1α,25-dihydroxy vitamin D3 enhances monocytic differentiation along with becoming resistant to apoptosis by induction of cytoplasmic p21 CIP1

International Journal of Oncology

Volumn 27, Issue 4, 2005, Pages 893-900

  Iguchi, Tomotaka ^a   Miyazawa, Keisuke ^a   Asada, Minoru ^b   Gotoh, Akihiko ^a   Mizutani, Shuki ^b   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Differentiation; Leukemia; Vitamin K2; Vitamin VD3

Indexed keywords

CALCITRIOL; CDKN1A PROTEIN, HUMAN; COLECALCIFEROL; CYCLIN DEPENDENT KINASE INHIBITOR 1A; FARNOQUINONE; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

APOPTOSIS; ARTICLE; BIOLOGICAL MODEL; CELL CYCLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN U937; CYTOLOGY; CYTOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LEUKEMIA; METABOLISM; MONOCYTE; MYELODYSPLASTIC SYNDROME; PATHOLOGY; TIME; TUMOR CELL LINE;

APOPTOSIS; CALCITRIOL; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CHOLECALCIFEROL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; HYDROGEN PEROXIDE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LEUKEMIA; MAP KINASE KINASE 4; MODELS, BIOLOGICAL; MONOCYTES; MYELODYSPLASTIC SYNDROMES; TIME FACTORS; TRANSFECTION; U937 CELLS; VITAMIN K 2;

EID: 33644816803     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.4.893     Document Type: Article

References (45)

1. Zhu J and Emerson SG: Hematopoietic cytokines, transcription factors and lineage commitment (Review). Oncogene 21: 3295-3313,2002.
2. Alcalay M, Orleth A, Sebastiani C, et at. Common themes in the pathogenesis of acute myeloid leukemia (Review). Oncogene 20:5680-5694,2001.
3. Westwood NB and Mufti GJ: Apoptosis in the myelodysplastic syndromes (Review). Curr Hematol Rep 3: 186-192, 2003.
4. Passegue E, Jamieson CH, Ailles LE and Weissman IL: Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics (Review)? Proc Natl Acad Sci USA 100: 11842-11849, 2003.
5. Miyazawa K, Nishimaki J, Katagiri T, el at Megakaryocytic maturation is regulated by maintaining a balance against cytokine induced-cell proliferation: steel factor retards thrombopoietin-induced megakaryocytic differentiation while synergistically stimulating mitogenesis. Hematology 5: 233-246, 2000.
6. Albanell J, Han W, Mellado B, Gunawardane R, Scher HI, Dmitrovsky E and Moore MA: Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. Cancer Res 56: 1503-1508, 1996.
7. Waxman S: Differentiation therapy in acute myelogenous leukemia (non-APL) (Review). Leukemia 14: 491-496, 2000.
8. Pitha-Rowe I, Petty WJ, Kitareewan S and Dmitrovsky E: Retinoid target genes in acute promyelocytic leukemia (Review). Leukemia 17: 1723-1730, 2003.
9. Chen SJ, Wang ZY and Chen Z: Acute promyelocytic leukemia: from clinic to molecular biology. Stem Cells 13: 22-31, 1995.
10. Tallman MS, Andersen JW, Schiffer CA, et al: All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med 337: 1021-1028, 1997.
11. Tsiftsoglou AS, Pappas IS and Vizirianakis IS: Mechanisms involved in the induced differentiation of leukemia cells (Review). Pharmacol Ther 100: 257-290, 2003.
12. Yaguchi M, Miyazawa K, Katagiri T, Nishimaki J, Kizaki M, Tohyama K and Toyama K: Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance of all-trans retinoic acid. Leukemia 11: 779-787, 1997.
13. Yaguchi M, Miyazawa M, Otawa M, et at Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody. Leukemia 12: 1392-1397, 1998.
14. Miyazawa K, Nishimaki J, Ohyashiki K, et al: Vitamin K2 therapy for myelodysplastic syndrome (MDS) and post-MDS acute myeloid leukemia: Information through a questionnaire survey of multi-center pilot studies in Japan. Leukemia 14: 1156-1157,2000.
15. Takami A, Nakao S, Ontachi Y, Yamauchi H and Matsuda T: Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol 69: 24-26, 1999.
16. Yaguchi M, Miyazawa K, Otawa M, Ito Y, Kawanishi Y and Toyama K: Vitamin K2 therapy for a patient with myelodysplastic syndrome. Leukemia 13: 144-145, 1999.
17. Fujita H, Tomiyama J and Tanaka T: Vitamin K2 combined with all-trans retinoic acid induced complete remission of relapsing acute promyelocytic leukemia. Br J Haematol 103: 584-585, 1998.
18. Sakai I, Hashimoto S, Yoda M, Hida T, Ohsawa S, Nakajo S and Nakayama K: Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. BiochemBiophysResCommun205: 1305-1310, 1994.
19. Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, Nishizawa Y, Yuo A and Ohyashiki K: Apoptosis/differentiationinducing effects of vitamin K2 on HL-60 Cells: Dichotomous nature of vitamin K2 in leukemia cells. Leukemia 15: 1111-1117, 2001.
20. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K and Mizutani S: Apoptosis inhibitory activity of cytoplasmic p21 (Cipl/WAFl) in monocytic differentiation. EMBOJ 18: 1223-1234, 1999.
21. Frankenberger M, Hofmann B, Emmerich B, Nerl C, Schwendener RA and Ziegler-Heitbrock HW: Liposomal 1,25 (OH)2 vitamin VD3 compounds block proliferation and induce differentiation in myelomonocytic leukaemia cells. Br J Haematol 98: 186-194, 1997.
22. Abe J, Morikawa M, Miyamoto K, et at. Differentiation of mouse myeloid leukemia cells induced by lα, 25-dihydroxyvitamin VD3. Proc Natl Acad Sci USA 78: 4490-4494, 1981.
23. Nishimaki J, Miyazawa K, Yaguchi M, et at. Vitamin K2 induces apoptosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation. Leukemia 9: 1399-1405, 1999.
24. Koester SK, Roth P, Mikulka WR, Schlossman SF, Zhang C and Bolton WE: Monitoring early cellular responses in apoptosis is aided by the mitochondrial membrane protein-specific monoclonal antibody AP02.7. Cytometry 29: 306-312, 1997.
25. Koeffler HP, Hirji K, Iri L and Southern California Leukemia Group: 1,25-Dihydroxyvitamin VD3 in vitro and in vivo effects on human preleukemia and leukemic cells. Cancer Treat Rep 69: 1399-1407, 1985.
26. Funato K, Miyazawa K, Yaguchi M, Gotoh A and Ohyashiki K: Combination of 22-oxa-l,25-dihydroxyvitamin VD3, a vitamin VD3 derivative, with vitamin K2 (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells. Leukemia 16: 1519-1527, 2002.
27. Kanda H and Miura M: Regulatory roles of JNK in programmed cell death. J Biochem 136: 1-6, 2004.
28. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002.
29. Vasilevskaya I and O'Dwyer PJ: Role of Jun and Jun kinase in resistance of cancer cells to therapy (Review). Drug Resist Updat 3: 147-156, 2003.
30. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
31. El-Deiry WS, Tokino T, Velculescu VE, et at. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
32. Rots NY, Iavarone A, Bromleigh V and Freedman LP: Induced differentiation of U937 cells by 1,25-dihydroxyvitamin VD3 involves cell cycle arrest in Gl that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 93: 2721-2729, 1999.
33. Asada M, Yamada T, Fukumuro K and Mizutani S: p21Cipl/WAFl is important for differentiation and survival of U937 cells. Leukemia 12: 1944-1950, 1998.
34. Poluha W, Poluha DK, Chang B, Crosbie NE, Schonhoff CM, Kilpatrick DL and Ross AH: The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 16: 1335-1341, 1996.
35. Cooper MP, Balajee AS and Bohr VA: The C-terminal domain of p21 inhibits nucleotide excision repair in vitro and in vivo. Mol Biol Cell 10: 2119-2129, 1999.
36. Taules M, Rodriguez-Vilarrupla A, Rius E, el at. Calmodulin binds to p21 (Cipl) and is involved in the regulation of its nuclear localization. J Biol Chem 274: 24445-24448, 1999.
37. Tanaka H, Yamashita T, Asada M, Mizutani S, Yoshikawa H and Tohyama M: Cytoplasmic p21(Cipl/WAFl) regulates neurite remodeling by inhibiting Rho-kinase activity. J Cell Biol 158:321-329,2002.
38. Suzuki A, Tsutomi Y, Yamamoto N, Shibutani T and Akahane K: Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist Fas-mediated cell death. Mol Cell Biol 19: 3842-3847, 1999.
39. Hoshi K, Nomura K, Sano Y and Koshihara Y: Nuclear vitamin K2 binding protein in human osteoblasts: homologue to glyceraldehyde-3-phosphate dehydrogenase. Biochem Pharmacol 58: 1631-1638, 1999.
40. MacDonald PN, Baudino TA, Tokumaru H, Dowd DR and Zhang C: Vitamin D receptor and nuclear receptor coactivators: crucial interactions in vitamin D-mediated transcription. Steroids 66: 171-176,2001.
41. Liu M and Freedman LP: Transcriptional synergism between the vitamin VD3 receptor and other nonreceptor transcription factors. Mol Endocrinol 8: 1593-1604, 1994.
42. Larson AE, Friedman PA and Suttie JW: Vitamin K-dependent carboxylase. Stoichiometry of carboxylation and vitamin K 2,3-epoxide formation. J Biol Chem 256: 11032-11035, 1981.
43. Akedo Y, Hosoi T, Inoue S, et at. Vitamin K2 modulates proliferation and function of osteoblastic cells in vitro. Biochem Biophys Res Commun 187: 814-820, 1992.
44. Tabb MM, Sun A, Zhou C, et at. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278: 43919-43927, 2003.
45. Yoshida Y, Anzai N and Kawabata H: Apoptosis in myelodysplasia: a paradox or paradigm. Leuk Res 19: 887-891, 1995.